Liu Pei, Jiang Huijuan, Che Mengting, Fu Rong, Wang Huaquan, Li Lijuan, Zhang Wei, Tao Jinglian, Gao Shan, Shao Zonghong
Department of Hematology, General Hospital of Tianjin Medical University, 154 Anshan St, Tianjin, China.
Department of Hematology, General Hospital of Tianjin Medical University, 154 Anshan St, Tianjin, China.
Leuk Res. 2018 Apr;67:12-16. doi: 10.1016/j.leukres.2017.11.010. Epub 2017 Dec 15.
To investigate the frequencies and biological characteristics of CD25 positive hematopoietic stem cells (HSC) in myelodysplastic syndromes.
The expression of CD25 on HSC in bone marrow derived from patients with untreated MDS patients, untreated AML patients and normal controls were accessed by flow cytometry (FCM). The correlation analysis was done between CD25 HSC and clinical parameters in MDS patients.
The expression of CD25 on HSC (CD34CD38 cells) in MDS patients (28.81%) was significantly higher than that in normal controls (9.41%, P = 0.020), which similar to that in AML patients (32.54%, P = 0.410). The CD25 expression on HSC was positively correlated with the CD123 expression on HSC (r = 0.602, P = 0.008). The expression of CD25 on HSC in high-risk MDS group (53.27%) based on IPSS score was significantly higher than that in low-risk MDS group (18.66%, P = 0.003). In MDS patients, CD25 HSC were negatively correlated with the counts of neutrophils (r = -0.684, P = 0.002) and platelets (r = -0.561, P = 0.015), while positively correlated with the percentage of blasts in bone marrow (r = 0.596, P = 0.009). The CD25 expression on erythroblasts had a significant positive correlation with red blood cell counts in MDS patients (r = 0.536, P = 0.012).
CD25 was over-expressed on HSC in MDS patients, especially in high-risk MDS patients. Increased CD25 HSC was correlated with progression of MDS. Low-expression of CD25 on erythroblasts might correlate with anemia in MDS patients. CD25 could be a specific marker of LSC in MDS, and could involve in the mechanisms of development and progression of MDS.
探讨骨髓增生异常综合征中CD25阳性造血干细胞（HSC）的频率及生物学特性。
采用流式细胞术（FCM）检测未经治疗的骨髓增生异常综合征（MDS）患者、未经治疗的急性髓系白血病（AML）患者及正常对照者骨髓中HSC上CD25的表达情况。对MDS患者中CD25+HSC与临床参数进行相关性分析。
MDS患者HSC（CD34+CD38-细胞）上CD25的表达率（28.81%）显著高于正常对照者（9.41%，P = 0.020），与AML患者（32.54%，P = 0.410）相似。HSC上CD25的表达与HSC上CD123的表达呈正相关（r = 0.602，P = 0.008）。基于国际预后评分系统（IPSS）评分的高危MDS组HSC上CD25的表达率（53.27%）显著高于低危MDS组（18.66%，P = 0.003）。在MDS患者中，CD25+HSC与中性粒细胞计数（r = -0.684，P = 0.002）和血小板计数（r = -0.561，P = 0.015）呈负相关，而与骨髓中原始细胞百分比呈正相关（r = 0.596，P = 0.009）。MDS患者红系细胞上CD25的表达与红细胞计数呈显著正相关（r = 0.536，P = 0.012）。
MDS患者HSC上CD25过度表达，尤其是高危MDS患者。CD25+HSC增加与MDS进展相关。红系细胞上CD25低表达可能与MDS患者贫血相关。CD25可能是MDS中白血病干细胞的特异性标志物，并可能参与MDS的发生发展机制。
